Literature DB >> 29552663

Micromanagement of drug-resistant advanced gastrointestinal stromal tumors: regorafenib-new ammunition in battling exon 17 mutations.

Alexander J Eckardt1, Ortwin Klein2.   

Abstract

Entities:  

Year:  2018        PMID： 29552663      PMCID： PMC5847923          DOI： 10.21037/tgh.2018.02.01

Source DB:  PubMed          Journal:  Transl Gastroenterol Hepatol        ISSN： 2415-1289


× No keyword cloud information.
  16 in total

1.  Two hundred gastrointestinal stromal tumors: recurrence patterns and prognostic factors for survival.

Authors:  R P DeMatteo; J J Lewis; D Leung; S S Mudan; J M Woodruff; M F Brennan
Journal:  Ann Surg       Date:  2000-01       Impact factor: 12.969

2.  Efficacy and safety of regorafenib in patients with metastatic and/or unresectable GI stromal tumor after failure of imatinib and sunitinib: a multicenter phase II trial.

Authors:  Suzanne George; Qian Wang; Michael C Heinrich; Christopher L Corless; Meijun Zhu; James E Butrynski; Jeffrey A Morgan; Andrew J Wagner; Edwin Choy; William D Tap; Jeffrey T Yap; Annick D Van den Abbeele; Judith B Manola; Sarah M Solomon; Jonathan A Fletcher; Margaret von Mehren; George D Demetri
Journal:  J Clin Oncol       Date:  2012-05-21       Impact factor: 44.544

3.  Comparison of performance of various tumour response criteria in assessment of regorafenib activity in advanced gastrointestinal stromal tumours after failure of imatinib and sunitinib.

Authors:  Atul B Shinagare; Jyothi P Jagannathan; Vikram Kurra; Trinity Urban; Judith Manola; Edwin Choy; George D Demetri; Suzanne George; Nikhil H Ramaiya
Journal:  Eur J Cancer       Date:  2014-01-02       Impact factor: 9.162

4.  Gain-of-function mutations of c-kit in human gastrointestinal stromal tumors.

Authors:  S Hirota; K Isozaki; Y Moriyama; K Hashimoto; T Nishida; S Ishiguro; K Kawano; M Hanada; A Kurata; M Takeda; G Muhammad Tunio; Y Matsuzawa; Y Kanakura; Y Shinomura; Y Kitamura
Journal:  Science       Date:  1998-01-23       Impact factor: 47.728

5.  Secondary mutations of c-KIT contribute to acquired resistance to imatinib and decrease efficacy of sunitinib in Chinese patients with gastrointestinal stromal tumors.

Authors:  Jing Gao; Ye Tian; Jian Li; Naiping Sun; Jiajia Yuan; Lin Shen
Journal:  Med Oncol       Date:  2013-03-02       Impact factor: 3.064

6.  Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors.

Authors:  George D Demetri; Margaret von Mehren; Charles D Blanke; Annick D Van den Abbeele; Burton Eisenberg; Peter J Roberts; Michael C Heinrich; David A Tuveson; Samuel Singer; Milos Janicek; Jonathan A Fletcher; Stuart G Silverman; Sandra L Silberman; Renaud Capdeville; Beate Kiese; Bin Peng; Sasa Dimitrijevic; Brian J Druker; Christopher Corless; Christopher D M Fletcher; Heikki Joensuu
Journal:  N Engl J Med       Date:  2002-08-15       Impact factor: 91.245

7.  Long-term follow-up results of the multicenter phase II trial of regorafenib in patients with metastatic and/or unresectable GI stromal tumor after failure of standard tyrosine kinase inhibitor therapy.

Authors:  E Ben-Ami; C M Barysauskas; M von Mehren; M C Heinrich; C L Corless; J E Butrynski; J A Morgan; A J Wagner; E Choy; J T Yap; A D Van den Abbeele; S M Solomon; J A Fletcher; G D Demetri; S George
Journal:  Ann Oncol       Date:  2016-07-01       Impact factor: 32.976

8.  Efficacy and safety of regorafenib for advanced gastrointestinal stromal tumours after failure of imatinib and sunitinib (GRID): an international, multicentre, randomised, placebo-controlled, phase 3 trial.

Authors:  George D Demetri; Peter Reichardt; Yoon-Koo Kang; Jean-Yves Blay; Piotr Rutkowski; Hans Gelderblom; Peter Hohenberger; Michael Leahy; Margaret von Mehren; Heikki Joensuu; Giuseppe Badalamenti; Martin Blackstein; Axel Le Cesne; Patrick Schöffski; Robert G Maki; Sebastian Bauer; Binh Bui Nguyen; Jianming Xu; Toshirou Nishida; John Chung; Christian Kappeler; Iris Kuss; Dirk Laurent; Paolo G Casali
Journal:  Lancet       Date:  2012-11-22       Impact factor: 79.321

Review 9.  Current research and treatment for gastrointestinal stromal tumors.

Authors:  Kheng Tian Lim; Kok Yang Tan
Journal:  World J Gastroenterol       Date:  2017-07-21       Impact factor: 5.742

10.  Efficacy and Safety of Regorafenib in Korean Patients with Advanced Gastrointestinal Stromal Tumor after Failure of Imatinib and Sunitinib: A Multicenter Study Based on the Management Access Program.

Authors:  Myoung Kyun Son; Min-Hee Ryu; Joon Oh Park; Seock-Ah Im; Tae-Yong Kim; Su Jin Lee; Baek-Yeol Ryoo; Sook Ryun Park; Yoon-Koo Kang
Journal:  Cancer Res Treat       Date:  2016-07-19       Impact factor: 4.679
View more
  1 in total

1.  Response letter on Micromanagement of drug-resistant advanced gastrointestinal stromal tumors: regorafenib-new ammunition in battling exon 17 mutations.

Authors:  Chun-Nan Yeh
Journal:  Transl Gastroenterol Hepatol       Date:  2018-06-19
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.